Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, in Relapsed or RefractoryMDS (Myelodysplastic Syndrome)
Investigational drug(s) / intervention(s)
Non interventional study
Non interventional study: Non Intervention, an observation LTFU study
Study summary
This study will evaluate the long-term safety of ARD103 cellular therapies
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.
* The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.
Exclusion Criteria:
* There are no specific exclusion criteria for this study
Primary outcome measure(s)
The incidence and duration of AEs, SAEs, and AESIs related to ARD103 treatment. — 15 years The number and percentages of participants experiencing TEAEs will be tabulated. Serious TEAEs will be summarized and AESIs will be summarized.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.